From the literature

This is a list of the peer-reviewed science that's coming through from the field of psychedelic psychiatry, and which informs this podcast.  

  1. Barrett, FS., Johnson, MW. & Griffiths., RR. 2017. Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences. Vol 15 (117): 155-160.
  2. Barrett, FS., Robbins, H., Smooke, D., Brown, JL. & Griffiths, RR. 2017. Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions. Frontiers in Psychology. Vol 8:1238.
  3. Bogenschutz., MP., Forcehimes, AA., Pommy, JA., Wilcox, CE., Barbosa, PCR. & Strassman, RJ. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology. Vol 29 (3): 289-99.
  4. Bogenschutz, MP. & Johnson, MW. 2016. Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology & Biological Psychiatry. Vol 64: 250-8. 
  5. Carbonaro, TM., Bradstreet, MP., Barrett, FS., MacLean, KA., Jesse, R., Johnson, MW. & Griffiths., RR. 2016. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology. Vol 30 (12):1268-1278.
  6. Carhart-Harris, RL. & Goodwin, GM. 2017. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology. Doi: 10.1038/npp.2017.84.
  7. De Veen, BT., Schellekens, AF., Verheij, MM. & Homberg, JR. 2017. Psilocybin for treating substance use disorders? Expert Review of Neurotherapeutics. Vol 17 (2): 203-212.
  8. Dos Santos, RG., Osório, FL., Crippa, JAS., Riba, J., Zuardi, AW. & Hallak, JEC. 2016. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology. Vol. 6 (3): 193–213.

  9. Garcia-Romeu, A., Griffiths, RR., & Johnson, MW. 2014. Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. Current Drug Abuse Reviews. Vol 7(3): 157-164.

  10. Griffiths, RR., Johnson, MW., Carducci, MA., Umbricht, A., Richards, WA., Richards, BD., Cosimano, MP. & Klinedinst, MA. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology. Vol 30 (12):1181-1197.

  11. Griffiths, RR., Johnson, MW., McCann, U., Richards, WA., Richards, BD. & Jesse., R. 2011. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. Vol 218 (4): 649-65. 

  12. Griffiths, RR., Richards, WA., Johnson, MW., McCann, UD & Jesse, R. 2008. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology. Vol 22(6): 621-632.
  13. Griffiths, RR., Richards, WA., McCann, U. & Jesse, R. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). Vol 187(3): 284-292.
  14. Hendricks, PS., Matthew W Johnson, MW. & Griffiths, RG. 2015. Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology. Vol. 29(9): 1041-1043. 
  15. Johnson, MW., Garcia-Romeu, A., Cosimano, MP. & Griffiths, RR. 2014. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology. Vol 28 (11): 983-992. 
  16. Johnson, MW., Garcia-Romeu, A. & Griffiths, RR. 2017. Longterm follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse. Vol 43 (1): 55-60.
  17. Johnson, MW. & Griffiths, RR. 2017. Potential Therapeutic Effects of Psilocybin. Neurotherapeutics. Vol 14 (3): 734-740.

  18. Johnson, MW., Garcia-Romeu, A. & Johnson, PS. 2017. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology. Vol 31 (7): 841-850.

  19. Johnson, MW., Richards, WA., & Griffiths, RR. 2008. Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology. Vol 22 (6): 603-620.

  20. Morgan, C., McAndrew, A. , Stevens. T., Nutt, D. & Lawn W. 2017. Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. Behavioral Sciences. 13: 71-76.
  21. Nichols, DE., Johnson, MW. & Nichols, CD. 2017. Psychedelics as Medicines: An Emerging New Paradigm. Clinical Pharmacology & Therapeutics. Vol 101 (2): 209-219.
  22. Roseman, L., Demetriou, L., Wall, MB., Nutt, DJ. & Carhart-Harris, RL. 2018. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. Vol 235 (2): 459-466.
  23. Thomas, K., Malcolm, B. & Lastra, D. 2017. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders. Journal of Psychoactive Drugs. Vol 8: 1-10.